甲状腺乳头状癌中放射性碘难治性、钠/碘同向转运体表达与突变之间的关联

The Association Between Radioiodine Refractory in Papillary Thyroid Carcinoma, Sodium/Iodide Symporter Expression, and Mutation.

作者信息

Anekpuritanang Tauangtham, Uataya Maythad, Claimon Apichaya, Laokulrath Natthawadee, Pongsapich Warut, Pithuksurachai Paveena

机构信息

Department of Pathology, Faculty of Medicine Siriraj Hospital, Mahidol University, Bangkok, 10700, Thailand.

Department of Otorhinolaryngology, Faculty of Medicine Siriraj Hospital, Mahidol University, Bangkok, 10700, Thailand.

出版信息

Onco Targets Ther. 2021 Jun 29;14:3959-3969. doi: 10.2147/OTT.S308910. eCollection 2021.

OBJECTIVE

To study the association between radioiodine refractory papillary thyroid carcinoma, sodium/iodide symporter (NIS) expression, and the mutation.

METHODS

A study was conducted on 30 radioiodine refractory papillary thyroid carcinoma patients and 30 radioiodine-avid papillary thyroid carcinoma patients. The expressions of sodium/iodide symporter and mutated protein were determined by immunohistochemistry using formalin-fixed, paraffin-embedded tissue.

RESULTS

The mutated protein was identified in 26 radioiodine refractory papillary thyroid carcinoma subjects (86.7%) and 22 radioiodine-avid papillary thyroid carcinoma subjects (73.3%), with no significant difference between the 2 groups ( = 0.3). Sodium/iodide symporter expression was detected in 4 of 30 cases (13.3%) from the radioiodine-avid papillary thyroid carcinoma group but was negative for all radioiodine refractory cases. There was no association between sodium/iodide symporter expression and radioiodine refractory papillary thyroid carcinoma ( = 0.11). Cases with positive NIS expression were likely negative for mutation (3/4; = 0.02).

CONCLUSION

Papillary thyroid carcinomas with mutation were more likely to be negative for NIS expression. mutation and NIS expressions cannot be used to predict radioiodine sensitivity.

目的

研究放射性碘难治性甲状腺乳头状癌、钠/碘同向转运体（NIS）表达与[具体基因名称]突变之间的关联。

方法

对30例放射性碘难治性甲状腺乳头状癌患者和30例放射性碘摄取型甲状腺乳头状癌患者进行研究。使用福尔马林固定、石蜡包埋组织，通过免疫组织化学法测定钠/碘同向转运体和[具体基因名称]突变蛋白的表达。

结果

在26例（86.7%）放射性碘难治性甲状腺乳头状癌患者和22例（73.3%）放射性碘摄取型甲状腺乳头状癌患者中检测到[具体基因名称]突变蛋白，两组之间无显著差异（P = 0.3）。放射性碘摄取型甲状腺乳头状癌组30例中有4例（13.3%）检测到钠/碘同向转运体表达，但所有放射性碘难治性病例均为阴性。钠/碘同向转运体表达与放射性碘难治性甲状腺乳头状癌之间无关联（P = 0.11）。NIS表达阳性的病例[具体基因名称]突变可能为阴性（3/4；P = 0.02）。